[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100478619":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":10,"centralContacts":22,"locations":32,"responsibleParty":48,"collaborators":10,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Henan Provincial People's Hospital","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Gene evolution of glioma in vivo",null,"Group A: gene evolution with relapsed. From the first day after the operation, the ctDNA was extracted from TISF before concurrent chemoradiotherapy as the baseline, and then the ctDNA was detected again after concurrent chemoradiotherapy. For the third time, ctDNA was detected in intensive chemotherapy with temozolomide. The image showed that the tumor progress was detected for the fourth time, and the ctDNA was detected for the fifth time when the tumor recurred. Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \\* 150mg\u002Fm2\u002Fday BSA(Body Surface Area)=\\[weight (kg)\\* height (cm)\u002F3600\\]2,",{"label":13,"type":10,"description":14,"interventionNames":15},"Gene evolution and molecular response under Bevacizumab treatment","After the recurrence, temozolomide combined with bevacizumab was used for chemotherapy, After bevacizumab was applied after six week , ctDNA is tested every six weeks. temozolomide combined with bevacizumab (600mg) in the course of tumor progression once a month.",[16],"Drug: Gene evolution and molecular response under Bevacizumab treatment",[18],{"type":19,"name":13,"description":20,"armGroupLabels":21,"otherNames":10},"DRUG","Patients with glioma were routinely treated with temozolomide chemotherapy from the 4th week after operation, for 5 days continuously, once every 4 weeks, with a single dose as follows: Single dose = BSA (body surface area) \\* 150mg\u002Fm2\u002Fday BSA(Body Surface Area)=\\[weight (kg)\\* height (cm)\u002F3600\\]2, According to the molecular pathological grade (WHO CNS5 grade), it is decided whether to combine radiotherapy (GBM combined with radiotherapy) and temozolomide combined with bevacizumab (600mg) in the course of tumor progression, Recording image changes",[13],[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Xingyao Bu, Ph.D","CONTACT","18538297990","xingyaob@zzu.edu.cn",{"name":29,"role":25,"phone":30,"phoneExt":10,"email":31},"Huibin Ning, Ph.D","15981849054","situhailuo@163.com",[33],{"facility":5,"status":10,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Zhengzhou","Henan","450003","China","CN",{"type":40,"coordinates":41},"Point",[42,43],113.64861,34.75778,{"lat":43,"lon":42},[46],{"name":47,"role":25,"phone":10,"phoneExt":10,"email":27},"Xingyao Bu",{"type":49,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100478619","study-on-gene-evolution-in-glioma-under-stress-therapy-100478619",false,"NCT05512325","Study on Gene Evolution in Glioma Under Stress Therapy","Study on Gene Evolution and Anti-VEGF Treatment Response of Different Subtypes of Glioma Based on ctDNA","Inclusion Criteria:\n\n* Age 18 to 75 years, both male and female (including 18 and 75 years old) glioma;\n* Willing to accept treatment and sign informed consent.\n\nExclusion Criteria:\n\n* Participants with other infection disease or immunodeficiency disease;\n* other central infectious diseases;\n* malignant tumor of non-nervous system;\n* drug abuse;\n* severe psychiatric disease;\n* uncontrolled diabetes;","ALL","18 Years","75 Years",{"count":61,"type":62},100,"ESTIMATED","5 Years","OBSERVATIONAL","Little is known about the evolution of genetic and epigenetic changes that occur in the progression of glioma. We inferred the evolution trajectories of matched pairs of primary tumors and progression tumor in situ fluid (TISF) based on deep whole-genome-sequencing data (ctDNA). A monocentric, Gene grouping controlled trial design was used to select patients. and to compare gene evolution of different subtypes of glioma under therapy. To predict the molecular reaction of bevacizumab treatment, clarify the mechanism of drug resistance of bevacizumab treatment.",[67],"Genetic Change",[69],"gene evolution, ctDNA, molecular response, Bevacizumab","NOT_YET_RECRUITING","2022-09-25",{"date":73,"type":74},"2022-09-27","ACTUAL",{"date":76,"type":62},"2022-12-17",{"date":78,"type":62},"2026-12-31",{"name":5,"class":6},1]